Pyxis Oncology, Inc. PYXS
Regular-session close
Pre-market · Nov 16, 7:22 AM ET
- YTD
- +37.39%
- 1 year
- -64.73%
- Market cap
- 188.98M
- Revenue (ttm)
- 16.15M
- EPS (ttm)
- -1.27
- Shares out
- 59.47M
- Forward P/E
- -1.40
- YTD return
- +37.39%
- 1-year return
- -64.73%
- Volume
- 359.90K
- Avg volume
- 990.53K
- Open
- 1.57
- Previous close
- 1.58
- Day's range
- 1.52 – 1.60
- 52-week range
- 1.03 – 5.55
- Beta
- 1.28
- Analysts
- Strong Buy
- Price target
- 10.00 (+532.9%)
5D -0.09 (-5.39%)
Key statistics
- Enterprise value
- -23.78M
- PEG ratio
- 0.00
- Price / sales
- 6.15
- Price / book
- 0.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -30.08M
- Total cash
- 144.82M
- Total debt
- 20.54M
- Return on equity
- -39.34%
- Short % of float
- 12.43%
- 50-day average
- 2.96
- 200-day average
- 3.68
Fundamental scorecard
5 of 25 checks passed on PYXS’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.32 | -0.35 | -0.03 | -9.38% |
| Aug 14, 2024 | Jun 1, 2024 | -0.33 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.33 | -0.29 | +0.04 | +12.12% |
| May 14, 2024 | Mar 1, 2024 | -0.27 | -0.06 | +0.21 | +77.78% |
| May 14, 2024 | Mar 1, 2024 | -0.27 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.49 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 20, 2024 | RBC Capital | reit | Outperform | Outperform |
| Nov 21, 2024 | RBC Capital | main | Outperform | Outperform |
| Nov 21, 2024 | William Blair | down | Outperform | Market Perform |
| Nov 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | Stephens & Co. | init | — | Overweight |
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pyxisoncology.com
News
RBC Capital Maintains Outperform on Pyxis Oncology, Raises Price Target to $7
Wedbush Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Pyxis Oncology Q3 EPS $(0.24) Beats $(0.29) Estimate
Pyxis Oncology To Present Late-Breaking Oral Data On MICVO Monotherapy In Previously Treated Recurrent/Metastatic Head And Neck Cancer At EORTC-NCI-AACR Symposium
Your note
Sign in to keep a note on PYXS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CIVIK THOMAS | Director | Stock Award(Grant) | Mar 23, 2023 | 221,886 |
| CLINE DARREN S | Director | Stock Award(Grant) | Mar 25, 2024 | 251,405 |
| CONNEALY PAMELA ANN | Chief Operating Officer | Purchase | Nov 25, 2024 | 0 |
| DUPONT JAKOB | Director | Stock Award(Grant) | Mar 25, 2024 | 38,741 |
| FLAVIN JOHN L. | Director | Stock Award(Grant) | Mar 25, 2024 | 413,015 |
| HUMPHREY RACHEL W M.D. | Director | Stock Award(Grant) | Mar 25, 2024 | 96,805 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 7.04% | 4,184,100 | 6.99M | Sep 29, 2024 |
| Laurion Capital Management, LP | 6.10% | 3,625,974 | 6.06M | Sep 29, 2024 |
| Blackrock Inc. | 4.98% | 2,964,160 | 4.95M | Sep 29, 2024 |
| Vanguard Group Inc | 4.09% | 2,432,953 | 4.06M | Sep 29, 2024 |
| Millennium Management Llc | 3.21% | 1,906,978 | 3.18M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 1.89% | 1,126,025 | 1.88M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.18% | 1,294,689 | 2.16M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.07% | 1,231,472 | 2.06M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.32% | 782,884 | 1.31M | Sep 29, 2024 |
| abrdn Healthcare Investors | 1.05% | 626,637 | 1.05M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.84% | 500,435 | 835.73K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.83% | 492,033 | 821.70K | Oct 30, 2024 |
